Champions Oncology (CSBR) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 was challenging, with annual revenue down 7% to $50.2 million and increased net loss, but operational improvements and strategic focus have positioned the company for renewed growth and profitability as seen in Q4.

• Q4 revenue rose 7% year-over-year to $14.0 million, with positive Adjusted EBITDA of $884,000, reversing a loss in the prior year.

• External biotech sector weakness and internal operational issues led to lower bookings, higher cancellations, and delayed revenue recognition.

• Management cited biotech sector funding challenges and large pharma spending patterns as key headwinds, but noted early signs of market recovery entering fiscal 2025.

• Strategic emphasis on large pharma customers and operational upgrades have begun to yield improved results.

Financial highlights

• Fiscal 2024 revenue was $50.2 million, down 7% year-over-year, with a net loss from operations of $7.4 million (GAAP), compared to $5.3 million loss in 2023.

• Adjusted loss (excluding $3.5 million non-cash expenses) was $3.9 million, versus $1.3 million in the prior year.

• Q4 revenue was $14 million, up 7% year-over-year; Adjusted EBITDA was $884,000, compared to a $900,000 loss in Q4 2023.

• Q4 pharmacology services gross margin expanded to 49% from 47% last year; full-year margin was 42%.

• Ended the year with $2.6 million in cash and no debt.

Outlook and guidance

• Management expects improved profitability and revenue growth in fiscal 2025, citing cost-cutting and operational efficiencies.

• Cautiously optimistic about returning to historical growth rates, pending further clarity on market recovery.

• G&A expenses anticipated to remain flat, with a reduced percentage of total revenue.

• No significant CapEx planned for the coming year.